<DOC>
	<DOCNO>NCT01410383</DOCNO>
	<brief_summary>Eprotirome liver selective thyroid hormone reduce several independent risk factor cardiovascular disease , euthyroid state preserve extrahepatic tissue . The purpose Phase III study assess long-term efficacy safety Eprotirome Patients heterozygous Familial Hypercholesterolaemia optimal standard care .</brief_summary>
	<brief_title>Efficacy Safety Study Eprotirome HeFH Patients Who Are Optimal Standard Care</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type II</mesh_term>
	<criteria>Patients confirm HeFH 18 year age screen Presence clinical atherosclerotic disease confers high risk CAD event together LDLC 2 mmol/L ( 80 mg/dL ) Presence risk factor CVD ( HeFH diagnosis ) together LDLC 2.5 mmol/L ( 100 mg/dL ) On optimal standard care , define stable dose statin ( rosuvastatin , atorvastatin , simvastatin ) without ezetimibe 8 week prior randomisation Significant health problem recent past include heart failure , cardiac electrophysiologic instability , rheumatoid arthritis , thyroid dysfunction , liver disease , cancer , secondary dyslipidaemia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>hypercholesterolemia ,</keyword>
	<keyword>dyslipidemia ,</keyword>
	<keyword>thyroid ,</keyword>
	<keyword>safety ,</keyword>
	<keyword>Heterozygous Familial Hypercholesterolaemia</keyword>
	<keyword>coronary artery disease</keyword>
</DOC>